Trial
NCT04261439
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Novartis Pharmaceuticals
Collaborators
—
Condition
In Escalation: All Patients With Solid Tumors and Lymphoma
Intervention
NIZ985
Why stopped
Sponsor's decision and not due to any safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-05-06